(NASDAQ: CRNX) Crinetics Pharmaceuticals's forecast annual revenue growth rate of 590.28% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.92%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.08%.
Crinetics Pharmaceuticals's revenue in 2026 is $1,535,000.On average, 16 Wall Street analysts forecast CRNX's revenue for 2026 to be $5,849,417,693, with the lowest CRNX revenue forecast at $2,334,149,480, and the highest CRNX revenue forecast at $11,213,368,733. On average, 11 Wall Street analysts forecast CRNX's revenue for 2027 to be $20,349,555,088, with the lowest CRNX revenue forecast at $14,105,672,016, and the highest CRNX revenue forecast at $32,379,942,563.
In 2028, CRNX is forecast to generate $52,286,352,758 in revenue, with the lowest revenue forecast at $30,316,045,043 and the highest revenue forecast at $99,446,648,320.